期刊文献+

艾塞那肽治疗肥胖2型糖尿病患者不良反应的观察与护理 被引量:2

下载PDF
导出
摘要 2型糖尿病是常见的慢性进展性疾病,传统上通过饮食、运动及口服降糖药治疗血糖控制不满意时,启用胰岛素治疗是控制血糖达标的主要手段,但常增加体重及低血糖风险,体重增加可进一步促进代谢综合征的发生与高心脑血管风险,低血糖可威胁患者生命安全,而且患者经常为了防治低血糖而过度的摄食,致使体重更难于控制。胰高血糖素样肽-1(GLP-1)是人体内一种主要的肠促胰素,艾塞那肽为GLP-1受体激动剂,可通过葡萄糖依赖方式促进内源性胰岛素分泌、抑制胰高血糖素、延缓胃排空、控制食欲而达到降血糖的作用。研究显示,
出处 《福建医药杂志》 CAS 2012年第5期157-159,共3页 Fujian Medical Journal
  • 相关文献

参考文献10

  • 1杨文英.解读预混胰岛素类似物双时相门冬胰岛素30在临床实践中的使用[J].中华糖尿病杂志,2010,2(3). 被引量:15
  • 2Kotsis V T, Stabouli S V, Papamichael C M, et al. Impact of obesity in intima media thickness of carotid arteries [J]. Obesi- ty, 2006, 14 (10): 1708-1715.
  • 3Miyawaki T, Abe M, Yahata K, et al. Contribution of viscer- al fat accumulation to the risk factors for atherosclerosis in non- obese Japanese [-J]. Intern Med, 2004, 43 (12) : 1138-1144.
  • 4Fehse F, Trautmann M, Holst J J, et al. Exenatide augments first-and second-phase insulin secretion in response to intrave- nous glucose in subjects with type 2 diabetes [J. J Clin Endo- crinol Metab, 2005, 90 (11): 5991-5997.
  • 5Horton E S, Silberman C, Davis K L, et al. Weight loss, gly- Cemic control, and changes in cardiovascular biomarkers in pa- tients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database I-J]. Diabetes Care, 2010, 33 (8) : 1759-1765.
  • 6Glass L C, Qu Y, Lenox S, et al. Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabe- tes: a pooled post-hoc analysis I-J]. Curr Med Res Opin, 2008, 24 (3): 639-644.
  • 7蒋建家,牟伦盼,苏劲波,孙炳庆,林振忠,毛艳玲,庄玉君,何芳,明德松.艾塞那肽对口服降糖药治疗欠佳的肥胖2型糖尿病患者的疗效及安全性[J].中华糖尿病杂志,2011,3(4):305-308. 被引量:18
  • 8蒋筠,彭永德.人GLP-1类似物治疗2型糖尿病的研究进展[J].世界临床药物,2010,31(2):74-77. 被引量:18
  • 9黄平,黄桂琼.糖尿病高血脂患者的生活方式健康教育及辨证施护[J].护理学报,2009,16(12):74-76. 被引量:15
  • 10Jones M C. Therapies for diabetes: pramlintide and exenatide [J]. Am Fam Physician, 2007, 75 (12): 1831-1835.

二级参考文献23

共引文献59

同被引文献34

  • 1李显丽,李奕平,王晓苓.艾塞那肽治疗肥胖2型糖尿病的临床疗效观察[J].昆明医科大学学报,2012,33(4):125-127. 被引量:4
  • 2Brubaker PL, Drucker DJ. Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and centralnervous system[J]. Endocrinology,2004,145 (6) :2653- 2659.
  • 3Parkes DG, Pittner R, Jodka C, et al. Insulinotropic actions of exendin4 and glucagon-like peptide-1 in vivo and in vitro [ J ]. Metabolism,2001,50(5) :583-589.
  • 4Moretto TJ, Milton DR, Ridge TD, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: A randomized, double- blind, placebo-controlled, parallel-group study [ J ]. Clin Ther, 2008 ,30 ( 8 ) : 1448-1460.
  • 5Norris SL, Lee N, Thakurta S, et al. Exenatide efficacy and safety: a systematic review [ J ]. Diabet Med, 2009 ,-26 ( 9 ) : 837- 846.
  • 6DeFronzo RA, Triplitt C, Qu Y, et al. Effects of exenatide plus rosiglitazone on 13-Cell function and insulin sensitivity in subjects with type 2 diabetes on mefformin [ J ]. Diabetes Care, 2010,33 (5) :951-957.
  • 7Traina AN, Lull ME, Hui AC, et al. Once-weekly exenatide as adjunct Ireatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy [ J ]. Can J Diabetes,2014,38 (4) :269-272.
  • 8Fu Z, Kuang HY, Hao M, et al. Protection of exenatide for retinal ganglion cells with different glucose concentrations [ J ]. Peptides,2012,37 ( 1 ) :25-31.
  • 9Bunck MC, Diamant M, Com6r A, et al. One-Year treatment with exenatide improves β-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients : a randomized, controlled trial [ J ]. Diabetes Care, 2009,32 ( 5 ) : 762-768.
  • 10Diamant M, Gaal LV, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes ( DURATION-3 ) : an open-label randomised trial [ J ]. Lancet,2010,375 (9733) :2234-2243.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部